Morgan Stanley
JSPRW icon

Morgan Stanley’s Japer Therapeutics Warrants JSPRW Stock Holding History

Morgan Stanley’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100
Closed -$12 – 7665
2023
Q2 		$12 Buy
+100
New +$15 ﹤0.01% 7596

Other funds holding JSPRW

CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ZA
Zazove Associates Incline Village, Nevada $1.22B AUM 1.91% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley's JSPRW Position: Q3 2023 in Review

Morgan Stanley sold out of Japer Therapeutics Warrants (JSPRW) in Q3 2023, closing a stake of 100 shares — an estimated $12 sold.

Morgan Stanley first reported a position in JSPRW in Q2 2023 and held it in 1 quarter. The position peaked at $12 in Q2 2023. 8 funds tracked by Wall St. Rank hold JSPRW as of Q3 2023.

  • Morgan Stanley reported no remaining Japer Therapeutics Warrants position as of Q3 2023 after selling out during the quarter.
  • Morgan Stanley sold 100 Japer Therapeutics Warrants shares in Q3 2023, an estimated $12.
  • Morgan Stanley first reported a position in Japer Therapeutics Warrants in Q2 2023 and held it in 1 quarter.
  • Morgan Stanley's Japer Therapeutics Warrants position peaked at $12 in Q2 2023.
  • 8 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.